{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mastitis-breast-abscess/prescribing-information/erythromycin-claithromycin/","result":{"pageContext":{"chapter":{"id":"35a080bd-68dc-5e30-8e45-c15b80ad6691","slug":"erythromycin-claithromycin","fullItemName":"Erythromycin and claithromycin","depth":2,"htmlHeader":"<!-- begin field 0390ed03-0709-401b-b728-a78200c4f9af --><h2>Erythromycin and clarithromycin</h2><!-- end field 0390ed03-0709-401b-b728-a78200c4f9af -->","summary":"","htmlStringContent":"<!-- begin item 82bd9f7c-3a93-4b54-86c9-a78200c4f815 --><!-- end item 82bd9f7c-3a93-4b54-86c9-a78200c4f815 -->","topic":{"id":"612445a9-31b6-5130-bb99-4389c0f9c4af","topicId":"8dd98aac-dd7a-4981-bb01-5e666b4686b6","topicName":"Mastitis and breast abscess","slug":"mastitis-breast-abscess","lastRevised":"January 2021","chapters":[{"id":"d054cbf1-e596-5afd-8a75-f3d051c621dc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"de83cb42-8301-5164-81a9-f0c4ab5a83c2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"610b1eb8-dd62-5e7e-b3bf-deb28c7072aa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c44cbf7c-02c4-5674-abb6-1c6be6131e3b","slug":"changes","fullItemName":"Changes"},{"id":"9d333c13-3643-5811-9a29-a919983994aa","slug":"update","fullItemName":"Update"}]},{"id":"f993c606-c828-51da-a43a-6029a7e07f40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4f11480-406f-5573-9e6b-b2747a513a11","slug":"goals","fullItemName":"Goals"},{"id":"5020b6cc-9441-50c0-b8dd-94fcf8bdf761","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"948e09e3-ff32-5344-a06f-e0a9331eff4f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e253dff2-3341-5c3a-8c2c-a8c5c9d27491","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7a7fe239-eefb-5a7a-936c-c1c01d919b6e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"844a01a3-e6d9-5962-905c-52aaa284973a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"13965c3c-cc8a-575f-8e2d-056c9590196a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"edd589e4-be3e-52d6-b1ea-c2095f08f38e","slug":"definition","fullItemName":"Definition"},{"id":"06b05f0c-3f18-5d1a-994a-02d388348b53","slug":"causes","fullItemName":"Causes"},{"id":"ac2b0ec4-d2dd-5b82-999f-aa4fb681433e","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"033ddd74-dfdc-5a2d-bb82-453baebee36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9ccd068b-aec1-59bb-a0dc-497e330227b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bf45f222-3e69-50c6-b73f-cd089ff22c65","slug":"complications","fullItemName":"Complications"}]},{"id":"1facde51-ce1f-55fa-889f-f079ac8b1283","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4d19871b-504c-5d1d-8e27-298e0a8e40b2","slug":"when-to-suspect-mastitis","fullItemName":"When to suspect mastitis"},{"id":"1a7eb0d1-33d6-539d-bfc3-0b12f1ec6451","slug":"when-to-suspect-a-breast-abscess","fullItemName":"When to suspect a breast abscess"},{"id":"3478864a-a09e-5e3f-ab1e-bd6dc34d0ae1","slug":"investigations","fullItemName":"Investigations"},{"id":"f70b7f79-5c5c-5a9d-a586-dad7ec33698c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1bdc74c8-e4f7-574c-a93a-ea9103718273","fullItemName":"Management","slug":"management","subChapters":[{"id":"7d9d079a-de35-5f76-8cfe-4303cce22c3e","slug":"management-lactating-women","fullItemName":"Scenario: Management - lactating women"},{"id":"95e2db4c-1f7a-5dfe-b04b-5edb440448bd","slug":"management-non-lactating-women","fullItemName":"Scenario: Management - non-lactating women"},{"id":"d1bd1c0d-5efe-5925-92a2-57663e0af1d5","slug":"management-breast-abscess","fullItemName":"Scenario: Management - breast abscess"}]},{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"02c4d465-606a-5a45-bb76-7884e6655d29","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"35a080bd-68dc-5e30-8e45-c15b80ad6691","slug":"erythromycin-claithromycin","fullItemName":"Erythromycin and claithromycin"},{"id":"3354cafa-cf61-54b5-8be9-14286cac7d43","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"6882319d-cec4-58ac-a5fb-bfad5a8c44b5","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"5ca61020-4e7e-58c8-89de-963d0f9fad55","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cdcf64dc-7d30-54dc-a4b3-c2cbb2e11318","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9ed2bf1e-0ab0-5318-ab26-7125ea334bc2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a07ffae7-9042-5683-b005-a39cb64cfe07","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3647fb21-13e1-5087-8638-500053de452d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d3f0e67e-27f7-5dab-bf77-6fd2fb6c04aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c1eba960-eb26-5c75-a69c-d1b75d6bb18b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e3453acf-65bd-5b33-854f-a6e08be6d75c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a7910f8f-ee5b-5ca4-ae1c-9f666dad5d78","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 947b73e2-d6b9-49c2-9baa-a78200c62e1f --><h3>Contraindications and cautions</h3><!-- end field 947b73e2-d6b9-49c2-9baa-a78200c62e1f -->","summary":"","htmlStringContent":"<!-- begin item 582131e3-e163-41af-a1f6-a78200c62c71 --><!-- begin field a1f2098b-0587-43dd-900d-a78200c62e1f --><ul><li><strong>Do not prescribe clarithromycin or erythromycin to people:</strong><ul><li>With known hypersensitivity to clarithromycin or erythromycin.</li><li>Taking certain drugs that prolong the QT interval — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li></ul></li><li><strong>Do not prescribe clarithromycin to people with severe hepatic impairment if they also have renal impairment.</strong></li><li><strong>Do not prescribe erythromycin to people with:</strong><ul><li>Porphyria.</li><li>Hypomagnesaemia.</li></ul></li><li><strong>Prescribe clarithromycin and erythromycin with caution in people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, conduction disturbances, or clinically relevant bradycardia.</li><li>Impaired hepatic function (or concomitantly receiving potentially hepatotoxic drugs) – clarithromycin and erythromycin are principally excreted by the liver.</li><li>Myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li><li><strong>Prescribe clarithromycin with caution in people with:</strong><br><ul><li>Hypomagnesaemia.</li><li>Severe renal impairment (eGFR less than 30 mL/min/1.73m<sup>2</sup>).<ul><li>Use half the normal dose. Avoid Klaricid XL® or clarithromycin modified-release preparations.</li></ul></li></ul></li><li><strong>Be aware of </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/prescribing-information/erythromycin-claithromycin/#drug-interactions\">drug interactions</a></strong><strong> with erythromycin and clarithromycin.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field a1f2098b-0587-43dd-900d-a78200c62e1f --><!-- end item 582131e3-e163-41af-a1f6-a78200c62c71 -->","subChapters":[]},{"id":"283bdeae-298a-59f7-946d-a793bd66c8dc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field aa515526-e12c-4061-839b-a78200c65064 --><h3>Adverse effects</h3><!-- end field aa515526-e12c-4061-839b-a78200c65064 -->","summary":"","htmlStringContent":"<!-- begin item d9a52f5e-92d6-4b45-adc7-a78200c64eb7 --><!-- begin field 3d833511-ebcc-4f23-8d83-a78200c65064 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides, but they are mild and less frequent with clarithromycin than with erythromycin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with erythromycin or clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with erythromycin and clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> have rarely been reported following treatment with erythromycin or clarithromycin.</li><li><strong>Reversible hearing loss (sometimes with tinnitus)</strong> can occur after large doses of erythromycin and clarithromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 3d833511-ebcc-4f23-8d83-a78200c65064 --><!-- end item d9a52f5e-92d6-4b45-adc7-a78200c64eb7 -->","subChapters":[]},{"id":"1ade9c13-355e-54ca-8a6f-a6e1e5c8c04f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 821bd3a9-cb1b-42ae-a7ac-a78200c673c8 --><h3>Drug interactions</h3><!-- end field 821bd3a9-cb1b-42ae-a7ac-a78200c673c8 -->","summary":"","htmlStringContent":"<!-- begin item b576f96e-a112-4329-b02f-a78200c670e2 --><!-- begin field 29446a0c-c099-42fa-9262-a78200c673c8 --><ul><li><strong>Key drug interactions with erythromycin and clarithromycin include: </strong><ul><li><strong>Carbamazepine </strong>— macrolides can raise plasma carbamazepine levels.<ul><li>For erythromycin — avoid concurrent use with carbamazepine unless carbamazepine levels can be closely monitored, and suitable dose adjustments made. Symptoms of carbamazepine toxicity (for example nausea, vomiting, dizziness, ataxia, and confusion) commonly begin within 1–3 days of starting erythromycin and usually resolve within 5 days of stopping erythromycin.</li><li>For clarithromycin — reduce carbamazepine dose by 30–50% and monitor plasma levels within 3–5 days of concurrent treatment with carbamazepine.</li></ul></li><li><strong>Drugs that prolong the QT interval (such as antiarrhythmics, antipsychotics, and tricyclic antidepressants) </strong>— all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia (such as diuretics, corticosteroids, short-acting beta-2 agonists) </strong>— hypokalaemia is a risk factor for QT interval prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin or erythromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe clarithromycin or erythromycin to a person taking simvastatin, as simvastatin is extensively metabolized by CYP3A4. If treatment with clarithromycin or erythromycin cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin — avoid concurrent use with clarithromycin or erythromycin, as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— erythromycin increases plasma concentrations of theophylline and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li><li>This interaction is less likely with clarithromycin unless theophylline levels are at the higher end of the therapeutic range.</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCB's metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Antidiabetic drugs and insulin</strong> — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly and adjust the antidiabetic drug (and/or insulin) dose accordingly.</li></ul></li></ul></li><li><strong>Contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after a course of clarithromycin or erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">FSRH, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">MHRA, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">Preston, 2020</a>]</p><!-- end field 29446a0c-c099-42fa-9262-a78200c673c8 --><!-- end item b576f96e-a112-4329-b02f-a78200c670e2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}